Bronchial Artery Embolization in Hemoptysis
Downloads
Hemoptysis, characterized by bleeding from the lower airways, is classified as mild, moderate, or massive, with massive hemoptysis carrying a mortality rate of 6.5–38%. Tuberculosis (TB) remains the most common cause globally. Management strategies include invasive and noninvasive options, with bronchial artery embolization (BAE) emerging as a cornerstone of noninvasive treatment since its introduction in the 1970s. Bronchial artery embolization provides rapid bleeding control and high success rates for both short- and long-term outcomes. Despite these advantages, recurrence rates range widely from 10–55%, often due to incomplete embolization, vessel recanalization, and collateral vessel development. The procedure employs embolic agents such as polyvinyl alcohol (PVA) particles, gelatin sponges, and tris-acryl gelatin microspheres, with minimal complications such as spinal cord infarction or broncho-esophageal fistulas. Diagnostic tools like computed tomography (CT) and bronchoscopy complement BAE by localizing the bleeding sites, stabilizing the airway, and aiding in definitive management. Bronchoscopy serves diagnostic and therapeutic purposes, employing techniques such as vasoconstrictor instillation, laser therapy, and balloon tamponade to control bleeding. Bronchial artery embolization is particularly effective for patients with life-threatening or recurrent hemoptysis who are unsuitable for surgery, often acting as a bridge to elective interventions. This literature review highlighted the pathophysiology, diagnostic modalities, BAE techniques, outcomes, and challenges involved in managing hemoptysis, emphasizing the role of BAE as a vital, minimally invasive therapeutic option.
Ittrich H, Bockhorn M, Klose H, et al. The Diagnosis and Treatment of Hemoptysis. Dtsch Arztebl Int 2017; 114: 371–381. [PubMed]
Li H, Ding X, Zhai S, et al. A Retrospective Study on the Management of Massive Hemoptysis by Bronchial Artery Embolization: Risk Factors Associated with Recurrence of Hemoptysis. BMC Pulm Med 2023; 23: 87. [PubMed]
Gupta A, Sands M, Chauhan NR. Massive Hemoptysis in Pulmonary Infections: Bronchial Artery Embolization. J Thorac Dis 2018; 10: S3458–S3464. [PubMed]
Coliat CM, Chang FY. An Unexpected Complication of Bronchial Artery Embolization in a Young Patient with Haemoptysis: A Case Report. Chest 2016; 150: 1031A. [Journal]
Kusumastrini YDS, Permatasari A. Bronchial Arteries Embolization in Tuberculosis-Related Recurrent Hemoptysis with Complete Right Lung Atelectasis: A Case Report. J Respirasi 2022; 8: 33–38. [Journal]
Ittrich H, Klose H, Adam G. Radiologic Management of Haemoptysis: Diagnostic and Interventional Bronchial Arterial Embolisation. Rofo 2015; 187: 248–259. [PubMed]
Bhalla A, Kandasamy D, Veedu P, et al. A Retrospective Analysis of 334 Cases of Hemoptysis Treated by Bronchial Artery Embolization. Oman Med J 2015; 30: 119–128. [PubMed]
Kathuria H, Hollingsworth HM, Vilvendhan R, et al. Management of Life-Threatening Hemoptysis. J Intensive Care 2020; 8: 23. [PubMed]
Nagano N, Suzuki M, Yamamoto S, et al. Short- and Long-Term Efficacy of Bronchial Artery Embolization Using a Gelatin Sponge for the Treatment of Cryptogenic Hemoptysis. Glob Heal Med 2022; 4: 315–321. [PubMed]
Mohamed AM, El Shimy A, Abdelaziz NAA, et al. Bronchial Artery Embolization Procedure for Treatment of Hemoptysis Caused by Cavitary Lung Lesions. Egypt J Hosp Med 2023; 90: 2701–2708. [Journal]
Walker CM, Rosado-de-Christenson ML, Martínez-Jiménez S, et al. Bronchial Arteries: Anatomy, Function, Hypertrophy, and Anomalies. Radiographics 2015; 35: 32–49. [PubMed]
Elhusseiny MM, Abd-Elhafez SAM, Amer TAY, et al. Bronchial Artery Embolization in Management of Hemoptysis: Safety and Efficacy. Egypt J Chest Dis Tuberc 2017; 66: 723–728. [ScienceDirect]
Singer ED, Faiz SA, Qdaisat A, et al. Hemoptysis in Cancer Patients. Cancers (Basel); 15. Epub ahead of print September 2023. [PubMed]
Aldiani A, Alatas MF. Pathophysiology of Haemoptysis in Lung Disease. J Respirologi Indones 2023; 43: 58–65. [Journal]
Sun VH, Carey DE, Som A, et al. Management of Hemoptysis with Bronchial Artery Embolization: Benign versus Malignant Indications. Am J Interv Radiol; 7. Epub ahead of print 2023. [Journal]
Nishihara T, Ishikawa H, Tsuyuguchi K, et al. Reevaluating the Role of Bronchoscopy Prior to Bronchial Artery Embolization in Nonintubated Patients with Hemoptysis Due to Bronchiectasis and Chronic Pulmonary Infection. CHEST Pulm; 3. Epub ahead of print 1 March 2025. [ScienceDirect]
Pei R, Zhou Y, Wang G, et al. Outcomes of Bronchial Artery Embolization for Life-Threatening Hemoptysis Secondary to Tuberculosis. PLoS One 2014; 9: e115956. [PubMed]
Sopko DR, Smith TP. Bronchial Artery Embolization for Hemoptysis. Semin Intervent Radiol 2011; 28: 48–62. [PubMed]
Almeida J, Leal C, Figueiredo L. Evaluation of the Bronchial Arteries: Normal Findings, Hypertrophy and Embolization in Patients with Hemoptysis. Insights Imaging 2020; 11: 70. [PubMed]
Lee JH, Yoon CJ, Jung YS, et al. Comparison of n-Butyl-2-Cyanoacrylate and Polyvinyl Alcohol Particles for Bronchial Artery Embolisation in Primary Lung Cancer: A Retrospective Cohort Study. Respir Res 2022; 23: 257. [PubMed]
Dorji K, Hongsakul K, Jutidamrongphan W, et al. Bronchial Artery Embolization in Life-Threatening Hemoptysis: Outcome and Predictive Factors. J Belgian Soc Radiol 2021; 105: 5. [PubMed]
Han K, Yoon KW, Kim JH, et al. Bronchial Artery Embolization for Hemoptysis in Primary Lung Cancer: A Retrospective Review of 84 Patients. J Vasc Interv Radiol 2019; 30: 428–434. [PubMed]
Zheng Z, Zhuang Z, Yang M, et al. Bronchial Artery Embolization for Hemoptysis: A Systematic Review and Meta-Analysis. J Interv Med 2021; 4: 172–180. [PubMed]
Copyright (c) 2025 Dea Putri Audina, Fathiyah Isbaniah, Dicky Soehardiman, Andi Darwis, Bagus Radityo Amien

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
1. The journal allows the author to hold the copyright of the article without restrictions.
2. The journal allows the author(s) to retain publishing rights without restrictions.
3. The legal formal aspect of journal publication accessibility refers to Creative Commons Attribution Share-Alike (CC BY-SA).
4. The Creative Commons Attribution Share-Alike (CC BY-SA) license allows re-distribution and re-use of a licensed work on the conditions that the creator is appropriately credited and that any derivative work is made available under "the same, similar or a compatible license”. Other than the conditions mentioned above, the editorial board is not responsible for copyright violation.